Q1 Earnings Estimate for Zura Bio Issued By Leerink Partnrs

Zura Bio Limited (NASDAQ:ZURA) – Analysts at Leerink Partnrs boosted their Q1 2025 earnings per share (EPS) estimates for Zura Bio in a report issued on Tuesday, March 25th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their previous forecast of ($0.15). The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.53) EPS and FY2026 earnings at ($0.48) EPS.

Other research analysts have also issued reports about the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $19.00 price target (down from $20.00) on shares of Zura Bio in a report on Wednesday. Guggenheim restated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Chardan Capital reduced their price objective on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $15.00.

Zura Bio Stock Down 6.6 %

Zura Bio stock opened at $1.27 on Friday. Zura Bio has a 12 month low of $1.07 and a 12 month high of $6.35. The company has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $2.73.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.09. The firm had revenue of $0.00 million during the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. American Century Companies Inc. bought a new position in Zura Bio in the 4th quarter valued at about $27,000. Prudential Financial Inc. acquired a new stake in shares of Zura Bio in the 4th quarter worth approximately $28,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Zura Bio in the third quarter valued at approximately $46,000. Two Sigma Advisers LP acquired a new position in shares of Zura Bio during the fourth quarter valued at approximately $32,000. Finally, ProShare Advisors LLC bought a new stake in Zura Bio during the fourth quarter worth approximately $35,000. 61.14% of the stock is owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.